MX2016003323A - Derivados de dosoxinojirimicina y sus metodos de uso. - Google Patents

Derivados de dosoxinojirimicina y sus metodos de uso.

Info

Publication number
MX2016003323A
MX2016003323A MX2016003323A MX2016003323A MX2016003323A MX 2016003323 A MX2016003323 A MX 2016003323A MX 2016003323 A MX2016003323 A MX 2016003323A MX 2016003323 A MX2016003323 A MX 2016003323A MX 2016003323 A MX2016003323 A MX 2016003323A
Authority
MX
Mexico
Prior art keywords
virus
influenza
viruses
deoxynojirimycin derivatives
dengue
Prior art date
Application number
MX2016003323A
Other languages
English (en)
Inventor
Ramstedt Urban
Penmasta Raju
Batra Hitesh
Nguyen Tam
Original Assignee
Emergent Virology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Virology Llc filed Critical Emergent Virology Llc
Publication of MX2016003323A publication Critical patent/MX2016003323A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud proporciona iminoazúcares novedosos y su uso en el tratamiento de infecciones virales, tales como infección de Dengue e infección de Influeza A. Los presentes inventores descubrieron que ciertos derivados de desoxinojirimicina pueden ser efectivos contra uno o más virus, los cuales pueden ser, por ejemplo, un virus de Dengue y/o un virus que pertenece a la familia Orthomyxoviridae, tal como un virus de Influenza A. En particular, estos derivados de desoxinojirimicina pueden ser útiles para tratar una enfermedad o condición causada por o asociada con uno o más virus. En ciertas modalidades los derivados de desoxinojirimicina pueden incrementar una tasa o probabilidad de supervivencia para un sujeto infectado con uno o más virus, los cuales pueden ser, por ejemplo, un virus de Dengue y/o un virus que pertenece a la familia Orthomyxoviridae, tal como un virus de Influenza A.
MX2016003323A 2013-09-16 2014-09-15 Derivados de dosoxinojirimicina y sus metodos de uso. MX2016003323A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361878286P 2013-09-16 2013-09-16
PCT/US2014/055599 WO2015039010A2 (en) 2013-09-16 2014-09-15 Deoxynojirimycin derivatives and methods of their using

Publications (1)

Publication Number Publication Date
MX2016003323A true MX2016003323A (es) 2016-08-12

Family

ID=52666528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003323A MX2016003323A (es) 2013-09-16 2014-09-15 Derivados de dosoxinojirimicina y sus metodos de uso.

Country Status (18)

Country Link
US (1) US10144727B2 (es)
EP (1) EP3046558B1 (es)
JP (1) JP6456393B2 (es)
KR (1) KR20160055916A (es)
CN (1) CN105636589B (es)
AP (1) AP2016009125A0 (es)
AU (1) AU2014318488B2 (es)
BR (1) BR112016005417A8 (es)
CA (1) CA2924026C (es)
CL (1) CL2016000597A1 (es)
CR (1) CR20160178A (es)
HK (1) HK1222129A1 (es)
IL (1) IL244446A0 (es)
MX (1) MX2016003323A (es)
PH (1) PH12016500465A1 (es)
RU (1) RU2702133C2 (es)
SG (1) SG11201601646YA (es)
WO (1) WO2015039010A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682914B2 (en) 2014-01-13 2017-06-20 P2 Science, Inc. Terpene-derived acids and esters and methods for preparing and using same
US10071944B2 (en) 2014-06-20 2018-09-11 P2 Science, Inc. Film ozonolysis in a tubular or multitubular reactor
EP3177587A4 (en) * 2014-08-06 2018-01-17 P2 Science, Inc. Fragrances from the esters of fatty acids
JP6826986B2 (ja) 2014-11-05 2021-02-10 エマージェント バイロロジー エルエルシー ウィルス性疾患の治療に有用なイミノ糖類
WO2017201052A1 (en) * 2016-05-16 2017-11-23 Emergent Virology Llc Methods of treating zika virus infection
WO2017201030A1 (en) * 2016-05-16 2017-11-23 Emergent Virology Llc Methods of treating viral infection
CA3026192A1 (en) 2016-06-21 2017-12-28 P2 Science, Inc. Flow-through reactors for the continuous quenching of peroxide mixtures and methods comprising the same
US10696605B2 (en) 2016-09-16 2020-06-30 P2 Science, Inc. Uses of vanadium to oxidize aldehydes and ozonides
CN111904959A (zh) * 2020-08-21 2020-11-10 牡丹江医学院 α-L-岩藻糖苷酶抑制剂在制备治疗小儿肺炎的药物中的用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2758025A1 (de) * 1977-12-24 1979-07-12 Bayer Ag Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
DE2834122A1 (de) 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
DE2853573A1 (de) 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3038901A1 (de) 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
DE3611841A1 (de) 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5043273A (en) 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US4994572A (en) 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US5200523A (en) 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
AU1876095A (en) 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
EP1037636A4 (en) 1997-12-11 2004-08-18 Univ Oxford INHIBITATION OF MEMBRANE-TIED VIRAL REPLICATION
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
GB9828474D0 (en) 1998-12-24 1999-02-17 British Aerospace Surface topology inspection
US6545021B1 (en) 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
AU1840101A (en) 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
US7427758B2 (en) 2003-05-28 2008-09-23 Opto-Knowledge Systems, Inc. Cryogenically cooled adjustable apertures for infra-red cameras
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
EP2023927B1 (en) 2006-05-24 2015-02-25 United Therapeutics Corporation Deoxynojirimycin and d-arabinitol analogs and methods of using
US20080138351A1 (en) 2006-08-02 2008-06-12 United Therapeutics Corporation Liposome treatment of viral infections
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
WO2009118658A2 (en) 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
WO2010027996A1 (en) * 2008-09-02 2010-03-11 Institute For Hepatitis And Virus Research Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
CA2753195C (en) 2009-02-23 2015-06-02 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
KR20170117614A (ko) 2009-02-24 2017-10-23 유나이티드 세러퓨틱스 코오포레이션 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법
WO2010109330A2 (en) 2009-03-27 2010-09-30 University Of Oxford Cholesterol level lowering liposomes
EP2440205B1 (en) 2009-06-12 2014-08-27 United Therapeutics Corporation Iminosugars for use in the treatment of bunyaviral and togaviral diseases
US20110065753A1 (en) 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating poxviral infections
EP2473046B1 (en) 2009-09-04 2014-10-22 United Therapeutics Corporation Iminosugars for their use in the treatment of filoviral diseases
US20110065752A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating orthomyxoviral infections
WO2014017915A2 (en) 2012-07-27 2014-01-30 Universiteit Utrecht Holding B.V. Urea and guanidinium derivatives of iminosugars

Also Published As

Publication number Publication date
SG11201601646YA (en) 2016-04-28
AU2014318488A1 (en) 2016-04-21
JP2016530332A (ja) 2016-09-29
AU2014318488A2 (en) 2016-04-28
EP3046558A2 (en) 2016-07-27
US10144727B2 (en) 2018-12-04
BR112016005417A8 (pt) 2020-02-18
PH12016500465B1 (en) 2016-05-16
CA2924026C (en) 2021-12-28
WO2015039010A2 (en) 2015-03-19
RU2702133C2 (ru) 2019-10-04
PH12016500465A1 (en) 2016-05-16
RU2016111704A3 (es) 2018-06-09
US20160221993A1 (en) 2016-08-04
EP3046558B1 (en) 2019-08-14
CN105636589B (zh) 2019-07-23
JP6456393B2 (ja) 2019-01-23
HK1222129A1 (zh) 2017-06-23
RU2016111704A (ru) 2017-10-23
CR20160178A (es) 2016-08-08
IL244446A0 (en) 2016-04-21
WO2015039010A3 (en) 2015-05-07
CN105636589A (zh) 2016-06-01
KR20160055916A (ko) 2016-05-18
AP2016009125A0 (en) 2016-04-30
EP3046558A4 (en) 2017-06-07
CL2016000597A1 (es) 2017-02-24
AU2014318488B2 (en) 2019-03-07
CA2924026A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
PH12015502230A1 (en) Novel viral replication inhibitors
ECSP14013315A (es) Inhibidores de aplicación viral
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
PH12017500207B1 (en) Indoles for use in influenza virus infection
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
PH12019500513A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
EA202091849A1 (ru) Тиазолидные соединения для лечения вирусных инфекций
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
CL2016000300A1 (es) Métodos terapéuticos
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
MY171497A (en) Crystalline forms of dihydropyrimidine derivatives
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
MX2016012104A (es) Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c.
PH12019501907A1 (en) Novel viral replication inhibitors
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii